October Pharma results, Q2 2026
Net profit, assets, equity and cash flow for Q2 2026, against the same period a year earlier, from the published financial statements.
Net profit144 millionEGP · +305.3% vs the same period a year earlier
In short
- October Pharma's net profit for Q2 2026 was about 144 million EGP, up +305.3% from 35.49 million EGP in Q2 2025.
Key lines against the same period a year earlier
This periodQ2 2025Change
Net profit144 million35.49 million+305.3%
Gross profit366 million164 million+123.3%
Total assets———
Total liabilities———
Shareholders' equity———
Total liabilities and equity1.29 billion1.39 billion−6.8%
Operating cash flow———
Investing cash flow———
Financing cash flow———
Net change in cash———
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
October Pharma's Q3 2026 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy